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Carbamazepine remains a ﬁrst-line drug for treatment of epilepsy in children. A wide variety of side
effects have been attributed to its use, including a mild involvement of the immune system, usually
a transient decline in IgA. Pulmonary complications, including interstitial pneumonitis, were mainly
described in adults, and are considered rare side effects. In this report we describe the ﬁrst pediatric
patient who developed a severe interstitial pneumonitis and a pan-hypogammaglobulinemia 2 months
after starting carbamazepine. A gradual resolution of symptoms and complete immune recovery was
observed after the drug withdrawal, but 6 months later our patient still has a marked reduction in lung
volumes and decreased exercise tolerance. We suggest that immunoglobulins should be carefully
examined after carbamazepine initiation, particularly if the patient develops any sign of
immunosuppression.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Carbamazepine (CBZ) is a drug of choice for treatment of simple
or complex partial seizures and generalized secondary seizures in
both children and adults.1 A wide variety of side effects have been
attributed to its use, including sleep disorders, anorexia, nausea,
vomiting, irritability, ataxia and diplopia. Involvement of the
immune system has been studied since the drug was ﬁrst used and
affects as many as 47% of patients,2 with a decrease in IgA levels
being the most commonly noted anomaly.3 IgG deﬁciency with B
cell aplasia has also been reported in some patients treated with
CBZ, due to a B cell maturation defect.4
While CBZ pulmonary toxicity is rare, interstitial pneumonitis,
bronchiolitis obliterans organizing pneumonia, bronchospasm,
pulmonary edema and pulmonary nodules have all been
reported.5,6
In this report we describe the case of a boy who developed an
interstitial pneumonitis and a pan-hypogammaglobulinemia
following CBZ therapy.: þ351 220835957.
il.com (D. Gonçalves),
rina@gmail.com (C. Ferraz),
etcabo.pt (L. Vaz).
-NC-ND license. 2. Patient presentation
A 7-year-old boy was being treated for epilepsy with valproic
acid, since he was 3 years old. Following a long assymptomatic
period, he had another seizure 2 months before admission, and CBZ
was started. Four weeks later, he presented to the emergency room
(ER) with fever, cough and dyspnea. Chest x-ray revealed a mild
interstitial inﬁltrate, and he was started on a 10-day course of
clarithromycin.
Since therewas no clinical improvement, the patient returned to
the ER. Pulmonary auscultation (PA) revealed ﬁne crackles and
wheezing bilaterally. He was discharged under systemic cortico-
steroid therapy (bethametasone) and inhaled short acting b2-
agonist (salbutamol).
Two weeks later he presented again with fever, non-productive
cough, asthenia and worsening dyspnea. On examination he had
a marked respiratory distress (tachypnea e 48 cycles/min e nasal
ﬂare, intercostal retractions) and hypoxemia (oxygen saturation of
84% in room air). PA again revealed diffuse crackles and wheezes in
both lungs. Initial investigations showed a hemoglobin of 11,5 g/dL,
white cell count of 18.2109/L (72% neutrophils, 12% lymphocytes),
platelet count of 338  109/L and a C-reactive protein of 35 mg/L.
Chest radiograph demonstrated bilateral interstitial inﬁltrates. He
was admitted under oxygen, ampicillin, oseltamivir, prednisone
and salbutamol, with a presumptive diagnosis of pneumonia. Blood
culture, viral antigen detection on nasal swab and serology for
atypical pneumonia were all negative. Computed tomography (CT)
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all pulmonary lobes, associated with peribronchial condensations
in the upper lobes, a pattern compatible with bilateral interstitial
pneumonitis. Steroid dosage was increased and ceftriaxone added
to the therapeutic regimen. There was no improvement in the
following days, with severe hypoxia and sustained fever. Due to
a possible need of admission in an Intensive Care Unit, he was
transferred to our pediatric department (tertiary care hospital).
Workup at this stage revealed pan-hypogammaglobulinemia
(IgG ¼ 163 mg/dL, IgA < 6 mg/dL, IgM < 5 mg/dL). Lymphocyte
subset showed normal numbers of CD4þ T cells (43,7%), CD8þ T
cells (38.9%) and almost absent CD19þ B cells (0.4%). A diagnosis of
CBZ hypersensitivity was suspected, and CBZ was replaced with
topiramate. An infusion of 600 mg/kg of IgG was performed.
A gradual clinical improvement was noted with a decrease in
the respiratory rate, work of breathing and oxygen requirement.
The child was discharged after 3 weeks, under a dose reduction
scheme of prednisone. Six months after CBZ discontinuation, the
patient had normalized quantitative immunoglobulins and
improved B cell numbers. Pulmonary function tests show
a restrictive pattern with a Forced Vital Capacity (FVC) of 53%, and
a normal FEV1/FVC ratio. He still has decreased exercise tolerance
and some limitation in performing activities of everyday life.
3. Discussion
The combination of worsening dyspnea, prolonged fever
without improvement, chest CT pattern of interstitial pneumonitisFig. 1. Computerized chest tomography.and pan-hypogammaglobulinemia, along with a 2-month interval
between the beginning of CBZ and the onset of symptoms, led to
the presumptive diagnosis of CBZ hypersensitivity. Furthermore,
a gradual resolution of symptoms and immune recovery was
observed after CBZ suspension. To our knowledge, this is the ﬁrst
case report of a pediatric patient with both an interstitial pneu-
monitis and a pan-hypogammaglobulinemia in association with
CBZ therapy.
Although the exact mechanisms of CBZ induced hypo-
gammaglobulinemia are unknown, absence of B cells, impairment
of immunoglobulin synthesis in B cells and a disorder of the class-
switch have all been implied.4,7 Recovery usually requires 4 months
to 6 years after drug withdrawal.8 In our patient, the most likely
mechanismwas the absence of B cells, probably due to direct bone
marrow suppression, as previously suggested.9 Since the patient
did not exhibit signs or symptoms of immunodeﬁciency before CBZ
administration, and the hypogammaglobulinemia with absent B
cells resolved after CBZ suspension, it is likely that CBZ therapy was
responsible for this serious defect in humoral immune response.
Conﬁrmation of the diagnosis with a further challenge with CBZ
was not thought to be justiﬁed.
CBZ-induced interstitial pneumonitis is a rare but well-
described complication5 in adults. The mechanism of lung injury
is believed to be an immune-mediated hypersensitivity response.10
In the present case, the thoracic CT ﬁndings and the clinical
improvement after CBZ withdrawal, suggest a CBZ-induced inter-
stitial pneumonitis. Despite the gradual improvement after the
drug withdrawal, our patient still has some exercise intolerance,
probably related to the marked decrease in lung volumes. Various
patterns of lung disease months to years after an initial CBZ
exposure have been reported before, mainly bronchiolitis obliter-
ans organizing pneumonia and drug induced lupus.5,6,11 Further
clinical follow-up along with thoracic CT imaging will reveal any
residual lung damage.
CBZ continues to be a ﬁrst-line drug for the treatment of
epilepsy in children. The present report calls attention to the need
for clinical follow-up of CBZ-treated children, due to its various side
effects, particularly affecting the immune system. We suggest that
immunoglobulins should be carefully examined in these children,
particularly after CBZ initiation. Moreover, concomitant CBZ
therapy should always be considered as a cause of interstitial
pneumonitis, since CBZ withdrawal is the only effective treatment
for further reducing lung injury.
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